Previous 10 | Next 10 |
2023-03-05 17:35:14 ET Major earnings expected after the bell on Monday include: Nutanix ( NTNX ) Cara Therapeutics ( CARA ) Trip.com Group Limited ( TCOM ) AeroVironment ( AVAV ) Intrepid Potash ( IPI ) For further details see: Notable ea...
2023-03-05 17:35:00 ET Anika Therapeutics ( NASDAQ: ANIK ) is scheduled to announce Q4 earnings results on Monday, March 6th, after market close. The consensus EPS Estimate is -$0.22 (+4.3% Y/Y) and the consensus Revenue Estimate is $37.71M (+5.3% Y/Y). Over the last 2...
BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2022 financial results after the close of the marke...
BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today issued the following statement in response to the letter by Caligan Partners LP: Over the last six months, members of Anika...
Caligan Partners Issues Open Letter to Anika Board PR Newswire Believes Current Board's Strategic Missteps and Poor Capital Allocation Has Led to Significant Underperformance Offers Three Actions for Significant Change, Including Strategic Review NEW ...
RevoMotion significantly expands Anika’s shoulder arthroplasty portfolio and provides a new solution in the over $800 million U.S. reverse shoulder market RevoMotion offers the industry’s smallest diameter threaded glenoid baseplate which preserves bone and enhances intrao...
Anika Therapeutics, Inc. (ANIK) Q3 2022 Results Conference Call November 08, 2022 05:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Dr. Cheryl Blanchard - President and Chief Executive Officer Mi...
Anika Therapeutics press release ( NASDAQ: ANIK ): Q3 Non-GAAP EPS of -$0.05 beats by $0.18 . Revenue of $40.3M (+1.9% Y/Y) beats by $2.71M . For further details see: Anika Therapeutics Non-GAAP EPS of -$0.05 beats by $0.18, revenue of $40.3M beats by $2....
Third Quarter Revenue Growth of 2% Third Phase III Clinical Trial for Cingal®, Next Generation Osteoarthritis Pain Product, Achieved Primary Endpoint Demonstrating Superiority Over Steroid Alone Pivotal Phase III Clinical Trial for Hyalofast®, HA-Based, Single-...
Study Demonstrated Superiority of Cingal, a Single-Injection Hyaluronic Acid-Based Viscosupplement Combined with Fast-Acting Steroid, Over Steroid Alone, for Osteoarthritis Pain Relief at 26 Weeks Study Builds on Prior Phase III Study Data that Demonstrated Superiority over Plac...
News, Short Squeeze, Breakout and More Instantly...
Anika Therapeutics Inc. Company Name:
ANIK Stock Symbol:
NASDAQ Market:
Anika Therapeutics Inc. Website:
Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika’s proprietary hyaluronic acid (HA) regenerative portfolio Over 300 surgeries completed during the limited market release, highlighting the growing interest and commerci...
2024-07-09 17:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 13:30:02 ET Stephens analyst issues EQUAL-WEIGHT recommendation for ANIK on May 29, 2024 12:00PM ET. The previous analyst recommendation was Equal-Weight. ANIK was trading at $25.32 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...